Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barré Syndrome.
Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barré Syndrome.